09:49 AM EST, 12/12/2024 (MT Newswires) -- Aptevo Therapeutics ( APVO ) shares were surging early Thursday after the company said all of the patients with acute myeloid leukemia treated with its mipletamig bispecific antibody achieved remission within 30 days of treatment in a phase 1b trial, including two patients in the cohort who experienced complete remission with 100% elimination of cancer cells.

The results build on data from the company's prior trial of the immune-oncology therapeutics platform, where 100% of the frontline patients also achieved remission, it said.

The phase 1b/2 dose optimization trial is investigating mipletamig as frontline therapy in up to 39 patients across five dosing levels in combination with venetoclax and azacitidine, which are the current standard of care for acute myeloid leukemia.

Price: 11.99, Change: +1.98, Percent Change: +19.78